Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression

Xia,Anzhou; Li,Huanhuan; Li,Ran; Lu,Linghong; Wu,Xiaoli

doi:10.3892/or.2018.6583

Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression

Authors:
- Anzhou Xia
- Huanhuan Li
- Ran Li
- Linghong Lu
- Xiaoli Wu
View Affiliations

Affiliations: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China, Department of Pharmacy, Huai'an First People's Hospital, Nanjing Medical University, Huaian, Jiangsu 223300, P.R. China
Published online on: July 20, 2018 https://doi.org/10.3892/or.2018.6583
Pages: 2353-2362

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling and upregulation of excision repair cross complementation group 1 (ERCC1) are the two most important factors that confer resistance to cisplatin (DDP) therapy in non-small-cell lung cancer (NSCLC). Therefore, inhibition of the PI3K/Akt/mTOR signaling pathway and ERCC1 expression is a potential approach for the treatment of patients with advanced NSCLC. In the present study, whether combined treatment with DDP and BEZ235, a dual PI3K/mTOR inhibitor, could provide a synergistic antitumor effect in A549/DDP cells was investigated, and the possible mechanisms involved were explored. The half-maximal inhibitory concentration (IC50) values were calculated in A549/DDP cells. Synergistic interaction of BEZ235 and DDP was evaluated by combination index (CI) analysis. The levels of phosphorylated Akt (p-Akt), phosphorylated mTOR (p-mTOR), apoptosis-related proteins and ERCC1 were detected by western blot analysis. Apoptotic cells were quantified by flow cytometry and Hoechst 33342 staining. The migration and invasion abilities of A549/DDP cells were evaluated by wound healing and Transwell assays, respectively. It was observed that the dose reduction index (DRI) of BEZ235 was 13.82 and for DDP it was 13.58, and the CI of combination was <1 over a wide range of doses. In addition, the levels of p-Akt, p-mTOR and ERCC1 were significantly elevated by DDP treatment, and were reduced by co-administration of BEZ235 and DDP. Furthermore, the combination treatment significantly induced apoptotic cell death, decreased migration and invasion abilities compared with those treated with either BEZ235 or DDP alone. In conclusion, the combination of BEZ235 with DDP had synergistic antitumor effects in A549/DDP cells as reflected by reduced proliferation, increased apoptosis, and suppression of the migration and invasion abilities of A549/DDP cells, and the mechanism mediating these effects may be associated with the inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
3	Morgensztern D, Ng SH, Gao F and Govindan R: Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey. J Thorac Oncol. 5:29–33. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ma D, Wang J, Hao X, Wang Y, Hu X, Xing P and Li J: Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis. Thorac Cancer. 8:482–488. 2017. View Article : Google Scholar : PubMed/NCBI
5	Jia Y, Zhou D, Jia Q, Ying Y and Chen S: Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft. Biomed Pharmacother. 79:27–34. 2016. View Article : Google Scholar : PubMed/NCBI
6	Müller A, Zang C, Chumduri C, Dörken B, Daniel PT and Scholz CW: Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer. 133:1813–1824. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sasore T, Reynolds AL and Kennedy BN: Targeting the PI3K/Akt/mTOR pathway in ocular neovascularization. Adv Exp Med Biol. 801:805–811. 2014. View Article : Google Scholar : PubMed/NCBI
8	Li H, Zhang B, Liu Y and Yin C: EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway. Med Oncol. 31:1622014. View Article : Google Scholar : PubMed/NCBI
9	Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M and Takeyama H: IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res. 160:90–101. 2010. View Article : Google Scholar : PubMed/NCBI
10	Burris HA III: Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB and Shu YQ: Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev. 13:2157–2162. 2012. View Article : Google Scholar : PubMed/NCBI
12	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
13	Tsodikov OV, Enzlin JH, Schärer OD and Ellenberger T: Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci USA. 102:11236–11241. 2005. View Article : Google Scholar : PubMed/NCBI
14	Cai Y, Yan X, Zhang G, Zhao W and Jiao S: The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Oncotarget. 6:18997–19005. 2015. View Article : Google Scholar : PubMed/NCBI
15	Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, et al: Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 65:377–382. 2009. View Article : Google Scholar : PubMed/NCBI
16	Palomba G, Atzori F, Budroni M, Ombra M, Cossu A, Sini M, Pusceddu V, Massidda B, Frau B, Notari F, et al: ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. J Transl Med. 12:2722014. View Article : Google Scholar : PubMed/NCBI
17	Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, et al: Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat. 42:101–106. 2010. View Article : Google Scholar : PubMed/NCBI
18	Wang S, Pan H, Liu D, Mao N, Zuo C, Li L, Xie T, Huang D, Huang Y, Pan Q, et al: Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer. Int J Oncol. 46:809–817. 2015. View Article : Google Scholar : PubMed/NCBI
19	Song W and Ma H: The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer. Onco Targets Ther. 9:3465–3471. 2016.PubMed/NCBI
20	Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, Kaina B and Köberle B: Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer. 9:2482010. View Article : Google Scholar : PubMed/NCBI
21	Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY and You HJ: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun. 327:225–233. 2005. View Article : Google Scholar : PubMed/NCBI
22	Qin X, Yao W, Li W, Feng X, Huo X, Yang S, Zhao H and Gu X: ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy. Tumour Biol. 35:4697–4704. 2014. View Article : Google Scholar : PubMed/NCBI
23	Herrera VA, Zeindl-Eberhart E, Jung A, Huber RM and Bergner A: The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer Res. 31:849–854. 2011.PubMed/NCBI
24	Chen L, Jin T, Zhu K, Piao Y, Quan T, Quan C and Lin Z: PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer. Oncotarget. 8:11937–11949. 2017.PubMed/NCBI
25	Xie G, Wang Z, Chen Y, Zhang S, Feng L, Meng F and Yu Z: Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response. Cancer Lett. 388:12–20. 2017. View Article : Google Scholar : PubMed/NCBI
26	Qu Y, Wu X, Yin Y, Yang Y, Ma D and Li H: Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. J Exp Clin Cancer Res. 33:522014. View Article : Google Scholar : PubMed/NCBI
27	Piao J, Chen L, Quan T, Li L, Quan C, Piao Y, Jin T and Lin Z: Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC. Oncotarget. 7:60169–60180. 2016. View Article : Google Scholar : PubMed/NCBI
28	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
29	Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
30	Torki S, Soltani A, Shirzad H, Esmaeil N and Ghatrehsamani M: Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells. Biomed Pharmacother. 92:39–45. 2017. View Article : Google Scholar : PubMed/NCBI
31	Eastman A: The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 34:155–166. 1987. View Article : Google Scholar : PubMed/NCBI
32	Torii Y, Kato R, Minami Y, Hasegawa K, Fujii T and Udagawa Y: ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. Anticancer Res. 34:107–115. 2014.PubMed/NCBI
33	Li Q, Tsang B, Bostick-Bruton F and Reed E: Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol. 57:347–353. 1999. View Article : Google Scholar : PubMed/NCBI
34	Fong MY and Kakar SS: The role of cancer stem cells and the side population in epithelial ovarian cancer. Histol Histopathol. 25:113–120. 2010.PubMed/NCBI
35	Yang H and Dou QP: Targeting apoptosis pathway with natural terpenoids: Implications for treatment of breast and prostate cancer. Curr Drug Targets. 11:733–744. 2010. View Article : Google Scholar : PubMed/NCBI
36	de Souza PM and Lindsay MA: Apoptosis as a therapeutic target for the treatment of lung disease. Curr Opin Pharmacol. 5:232–237. 2005. View Article : Google Scholar : PubMed/NCBI
37	Li QQ, Lee RX, Liang H, Zhong Y and Reed E: Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol. 30:4242013. View Article : Google Scholar : PubMed/NCBI
38	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
39	Sun A, Chia JS, Chiang CP, Hsuen SP, Du JL, Wu CW and Wang WB: The chinese herbal medicine Tien-Hsien liquid inhibits cell growth and induces apoptosis in a wide variety of human cancer cells. J Altern Complement Med. 11:245–256. 2005. View Article : Google Scholar : PubMed/NCBI
40	Neuzil J, Tomasetti M, Mellick AS, Alleva R, Salvatore BA, Birringer M and Fariss MW: Vitamin E analogues: A new class of inducers of apoptosis with selective anti-cancer effects. Curr Cancer Drug Targets. 4:355–372. 2004. View Article : Google Scholar : PubMed/NCBI
41	Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z and Cullen KJ: Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis. Clin Cancer Res. 12:5817–5825. 2006. View Article : Google Scholar : PubMed/NCBI
42	Yan M, Ni J, Song D, Ding M and Huang J: Activation of unfolded protein response protects osteosarcoma cells from cisplatin-induced apoptosis through NF-κB pathway. Int J Clin Exp Pathol. 8:10204–10215. 2015.PubMed/NCBI
43	Wolf BB, Schuler M, Echeverri F and Green DR: Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem. 274:30651–30656. 1999. View Article : Google Scholar : PubMed/NCBI
44	Yu Y, Yu X, Ma J, Tong Y and Yao J: Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells. Int J Oncol. 49:285–293. 2016. View Article : Google Scholar : PubMed/NCBI
45	Bhende PM, Park SI, Lim MS, Dittmer DP and Damania B: The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia. 24:1781–1784. 2010. View Article : Google Scholar : PubMed/NCBI